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treatment for more than 1 year reduced late stent thrombosis and ischemic events after drug-eluting stents (DES), but increased the risk of bleeding. 7 Dual antiplatelet therapy, together with aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor), is a standard follow-up therapy for CAD patients after PCI treatment. 9 As the most serious complication associated with ischemic events after DES, stent thrombosis often leads to myocardial infarction. 10 Compared with aspirin treatment, the combined treatment of aspirin with clopidogrel can reduce the risk of cardiovascular death. 11 Rudolph et al 12 revealed that use of clopidogrel for stable CAD patients with long-term aspirin treatment might lead to short-term increase in endothelial function. Besides of that, about 40%
of clopidogrel-treated patients displayed a high on-treatment platelet reactivity (HPR). 13 Platelet activation and aggregation were the pathophysiological basis of various atherosclerotic thrombosis and coronary stent thrombosis, 14 which might induce the recurrence of ischemic cardiovascular adverse events. Numerous clinical trials found that DAPT could reduce the higher risk of major adverse cardiovascular events in CAD patients. However, there are still some CAD patients suffering from thrombotic events, which might be related to HPR. 14, 15 The function of CYP2C19 polymorphisms was inconsistent with different types of diseases. The CYP2C19*17 gain-of-function (GOF) variant was found to be related to ultrarapid enzymatic activity. Patients with CYP2C19*17 gene had considerably lower adenosine diphosphate-induced platelet aggregation and higher risk of bleedings. 15 However, in CHANCE trial (clopidogrel in high-risk patients with acute nondisabling cerebrovascular events, a genetic study), reduced stroke recurrence could not be found in patients with clopidogrel-aspirin with CYP2C19 loss-of-function (LOF) allele (*2 and *3), 16 indicating that CYP2C19 LOF negatively influenced the effect of clopidogrel on CAD patients. To get an in-depth insight into the influence of CYP2C19 on clopidogrel treatment of CAD, further studies were needed to explore more specific properties of CYP2C19 polymorphisms. Previous studies have indicated that the ABCB1 gene could affect clopidogrel absorption and encode an intestinal efflux pump. 17, 18 In addition, patients with ABCB1 3435CT (rs1045642) genotype had an increased propensity for ischemic outcomes after acute coronary syndrome when treated with PCI and clopidogrel. 19 Therefore, we speculated that ABCB1 exerted an influence on the recurrence of ischemic cardiovascular adverse events.
We have long paid attention to CYP2C19 and ABCB1 because of their close association with coagulation and clopidogrel absorption. Thus, in this study, we intended to investigate the influence of CYP2C19 and ABCB1 polymorphisms on the recurrence of ischemic cardiovascular adverse events in patients with coronary artery disease treated with clopidogrel. 
| MATERIALS AND METHODS

| Study population and design
| Platelet agglutination function testing
Venous blood was extracted from patients on an empty stomach in the morning 3 days after PCI operation. Extracted venous blood was Patients with PIR ≥30% were in normal group. Patients with PIR <30%
were in HPR group.
| CYP2C19 and ABCB1 genotyping
Two millilitre venous blood of every patient was extracted and collected into an EDTA anticoagulant tube (Biotend, Shanghai, China).
The samples were preserved at 20°C before detection. Blood genomic DNA isolation kit (DP318, TIANGEN Biotech, Beijing, China) was used to extract DNA samples. Q3000 ultraviolet spectrophotometer (Quawell, San Jose, CA, USA) was employed to detect the concentration of DNA. Extracted DNA was amplified by qRT-PCR and crossbred. Primer sequences were indicated in Table 1 . CYP2C19*2 (rs4244285), CYP2C19*3 (rs4986893), and ABCB1 3435CT (rs1045642) were mainly examined. The polymorphism of all patients was categorized into CYP2C19*2 (rs4244285),
CYP2C19*3 (rs4986893) and ABCB1 3435CT (rs1045642). CYP2C19
was subgrouped into three genotypes: wild type (G/G), heterozygous mutant type (G/A), and homozygous mutant type (A/A).
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ABCB1 was divided into three genotypes: wild type (C/C), heterozygous mutant type (T/C), and homozygous mutant type (T/T). The
representative results of sequence-based typing were depicted in 
| Statistical analysis
Clinical statistical analyses were carried out using SPSS 20.0 software (SPSS, Chicago, IL, USA). All variables were tested for normal distribution using Kolmogorov-Smirnov test (KS test). Measurement data were analyzed using t test, and enumeration data were analyzed using 
| RESULTS
| The general information and platelet function of patients
A total of 168 CAD patients after clopidogrel treatment were followed up, and clinical data were recorded. The number of patients in HPR group was 50 in total (50/168). The other 118 patients were assigned to the normal group. As shown in Table 2 , there was no significant difference between the general demographic features (age, gender, height, weight, and body mass index) and HPR. Also, no difference was seen between CAD risk factors (smoking, drinking, high blood pressure, HLP, and diabetes) and HPR.
| Incidence of cardiovascular adverse events
All patients were follow-up visited within 24 months after PCI operation. The incidence of cardiovascular ischemic events and Seventeen patients (14.41%) were found to have bleeding events, including 2 cases of hemorrhagic apoplexy, 9 cases of secondary anemia, and 6 cases of hemorrhage of digestive tract. In HPR group (n = 50), 47 patients showed ischemic events (94.00%), including 3 cases of cardiac death, 4 cases of myocardial infarction, 17 cases of angina recurrence, and 23 cases of stent thrombosis. However, no bleeding events were found in HPR group. All the above results indicated that patients in HPR group had a significantly higher incidence of cardiovascular ischemic events (Table 3) . Therefore, HPR might be an independent predictive factor of cardiovascular ischemic adverse events.
| CYP2C19 and ABCB1 genotypes distribution
The specific distribution of CYP2C19 and ABCB1 genotypes was shown in Table 4 T A B L E 5 Gene mutation distribution among the patients
F I G U R E 2 Correlation between genotype and platelet inhibition ratio (PIR) and high on-treatment platelet reactivity (HPR). (A) HPR rate
of patients with CYP2C19*3 was significantly higher than that of patients with CYP2C19*2 and ABCB1 3435CT. (B) Average PIR of patients with CYP2C19*3 was significantly lower than that of patients with CYP2C19*2 and ABCB1 3435CT. PIR: platelet inhibition ratio; HPR: high on-treatment platelet reactivity. **P < .01, ***P < .001, compared with CYP2C19*3 group. CYP2C19: cytochrome P450 family 2 subfamily C member 19; CYP2C19*2: rs4244285; CYP2C19*3: rs4986893; ABCB1: ATP binding cassette subfamily B member 1; ABCB1 3435CT: rs1045642 49.40% mutation frequency. ABCB1 T/T was observed in 26 patients with 15.48% mutation frequency.
The gene mutation rate of patients with CYP2C19*3 in HRP group (81.82%) was significantly higher than that in normal group (18.18%).
Average PIR of patients with CYP2C19* was also significantly higher than that of other patients (Table 5 , Figure 2 ). All the above results demonstrated that CYP2C19*3 mutation could be considered as an independent predictive factor of post-PCI HPR and cardiovascular adverse events, whereas CYP2C19*2 and ABCB1 genetic mutation was not significantly correlated with HPR.
| Multivariate logistic regression analysis
Multivariable logistic regression analysis showed that CYP2C19*3 might serve as an independent predictive factor of post-PCI HPR Table 7 ).
| DISCUSSION
Patients with HPR had a higher recurrence rate of cardiovascular adverse events after PCI operation and clopidogrel treatment. Besides of that, patients with CYP2C19*3 mutation had a significantly higher incidence of HPR, whereas CYP2C19*2 and ABCB1 mutation was not significantly correlated with HPR incidence. CYP2C19*3 might act as an independent predictive factor of post-PCI HPR. In addition, CYP2C19*3 as well as post-PCI HPR could function as independent predictive factors of cardiovascular adverse events.
Genetic factors contribute to an increase in CAD occurrence and incur major complications such as HPR-related stent thrombosis, which is commonly presented as myocardial infarction. 20 Although the combined therapeutic strategy of DAPT with aspirin and clopidogrel has been widely applied to the treatment of CAD, the efficacy of clopidogrel can be influenced by CYP2C19*3 LOF allele. 21 In our study, higher incidence of cardiovascular ischemic adverse events was found in HPR group. Therefore, we speculated that HPR might function as an independent predictive factor of cardiovascular ischemic adverse events.
Among the mutated genotypes of CYP2C19 and ABCB1, CYP2C19*3
LOF was highly correlated with HPR occurrence and PIR, whereas CYP2C19*2 and ABCB1 3435CT had no significant relationship with HPR and PIR. Taken together, CYP2C19*3 LOF could be an independent predictive factor of HPR and ischemic cardiovascular adverse events.
In the current study, 168 CAD patients were follow-up visited within 24 months after PCI operation and clopidogrel treatment, with all clinical data recorded. Collected data indicated that patients in HPR group had significantly higher recurrence rate of cardiovascular ischemic events. Several previous study results were also consistent with the current findings. For instance, Bagai et al 22 reported that a high residual platelet reactivity on clopidogrel treatment was found in their study, in which 40% of patients had HPR. Zhang et al 23 revealed that the occurrence of HPR could be regarded as an independent predictor of 2-year stent thrombosis following DES implantation in patients treated with both aspirin and clopidogrel. and induce stent thrombosis. 28 We found specifically that CYP2C19*3 polymorphism was closely correlated with HPR. Although CYP2C19*2 was indicated to have higher gene mutation rate in patients with HPR, while CYP2C19*3 had lower mutation rate in patients with HPR.
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CYP2C19*3 genetic polymorphism has higher predictive value for HPR.
In addition, in our study, there was a remarkably higher gene mutation rate of CYP2C19*3 in CAD patients with HRP, and these patients with HPR presented a significantly higher incidence of ischemic cardiovascular adverse events. Therefore, we concluded that CYP2C19*3 genetic polymorphism could function as an independent predictive factor of ischemic cardiovascular events. These study results contributed to not only the understanding of correlation of CYP2C19 and ABCB1 genetic polymorphisms with ischemic cardiovascular adverse events, but also the development of effective therapeutic approach of adverse cardiovascular events after clopidogrel treatment of CAD patients.
However, there were still some limitations in the present study.
For one thing, a limited number of study objects might not be sufficient to completely substantiate the conclusion. The results would be more convincing when a larger cohort was employed in the future. In addition, stronger evidence for the risk factor analysis of incidence of cardiovascular adverse effects should be further investigated.
In conclusion, CYP2C19*3 might function as an independent predictive factor for HPR and ischemic cardiovascular adverse events, whereas CYP2C19*2 and ABCB1 mutant genes could not predict HPR and ischemic cardiovascular adverse events. Therefore, it should be tested before clopidogrel treatment for CAD patients, which could help make individualized treatment plans for patients.
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